Based on the results of our study, we conclude that the effect of common polymorphisms in IGF2BP2, HHEX, CDKN2A/B, SLC30A8, PPARG, and KCNJ11, all of which have been previously associated with T2DM, is not pronounced in the risk of NODAT in kidney transplant recipients treated with tacrolimus. This evidence concerns the gene SLC30A8 and type 2 diabetes mellitus.